TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04249037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)
Description: A 30 day supply of Bictegravir 50mg/Emtricitabine 200mg/Tenofovir Alafenamide 25mg will be provided to the rapid start arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard initiation of antiretroviral therapy (ART)
Description: Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
Study: NCT03774953

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and vitamin supplementation
Description: The intervention group will receive 1.5 g protein/kilo/day during hospitalization and a standard dose of 27 g protein/day in 60 days after discharged together with a daily dose of vitamin/mineral supplement
Study: NCT01874847

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days
Study: NCT02091284

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
Study: NCT01596335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650
Description: TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
Description: VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
Study: NCT00946725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
Study: NCT01874847

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill will be given, one capsule, once at night, for 28 days
Study: NCT01411709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitano
Description: two 200mg tablets per day for 14 days
Study: NCT02604251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic WoundGel System
Description: Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
Study: NCT01359449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®
Description: 0.5 mL, Intramuscular
Study: NCT01708018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WATSU
Description: WATSU (WaterShiatsu) is a gentle form of hydrotherapy that was established in the 1980s. The standardized 60min-intervention applied in this trial is called WATSU-Transition-Flow (Dull, 1997) and is adapted for the third trimester. The mother's abdomen is not being touched during the treatment.~The treatment takes place in a one-to-one hands-on-setting in the warm- water-therapy-pool (35°C, 95°F) of the University Hospital in Bern and consists of acupressure massage according to the Japanese massage-technique Shiatsu, in an attempt to harmonize the mother's energy-flow in the so called meridians (energy-channels) of Traditional Chinese Medicine. These meridians are also sought to be influenced by slow passive stretches of the mother's extremities. In addition, mobilization of her spine is being enhanced by gravity-free movements.~During the study, each participant in the intervention group will be treated twice with WATSU (60min treatment at day 1 and 4).
Study: NCT02352012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous blood
Description: Autologous blood was perfused to the target pulmonary segment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchial plug
Description: Bronchial plug was placed to the target pulmonary segment
Study: NCT03815526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic tape
Description: Dynamic tape apply 1 time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Dynamic tape apply 1 time
Study: NCT01883011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piracetam

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02161276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNTL capsule
Description: Patients were asked to taken drugs 3 times a day, with each time 3 grains

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients were asked to taken drugs 3 times a day, with each time 3 grains
Study: NCT03993223

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Upper trapezius muscle fatigue
Description: Isometric contraction of scapular elevation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper trapezius muscle fatigue
Description: Isometric contraction of scapular elevation
Study: NCT01151761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 100 mg/m2, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2, based on Calvert formula, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 200 mg/m2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Study: NCT02333890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: chloroquine 500 mg daily as an oral capsule during the wait time to surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00702494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB-403
Description: Multiple IV
Study: NCT03369431

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vivomixx
Description: Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vivomixx
Description: Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: 4.4 grams of maltose and silicon dioxide per sachet

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: 4.4 grams of maltose and silicon dioxide per sachet
Study: NCT00509093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: AF1q gene analysis (on bone marrow aspirate)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
Study: NCT03095820

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain intervention
Study: NCT02753634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Square-stepping exercise
Description: Participants are asked to remember and repeat stepping patterns across a gridded mat as shown to them by an instructor.
Study: NCT03299543

Intervention type: DEVICE
Intervention: LEVL (Medamonitor)
Description: Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone
Study: NCT06300866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: toothpaste containing 0.76% sodium monofluorophosphate
Study: NCT04264260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Tablets
Description: three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
Study: NCT00558961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec and Chlorambucil
Description: The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
Study: NCT01054794

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gastric mucosal stimulation
Description: The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric mucosal stimulation
Description: The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
Study: NCT01482598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Care Follow up
Description: Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
Study: NCT03845010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalol
Description: Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide and verapamil
Description: Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine
Study: NCT03452397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
Description: 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
Description: 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
Description: 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Placebo (vehicle) nasal spray
Study: NCT01590810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 2.0 mg
Description: Single oral 2.0-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 10 mg
Description: Single oral 10-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 40 mg
Description: Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 90 mg
Description: Single oral 90-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 5.0 mg
Description: Single oral 5.0-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 20 mg
Description: Single oral 20-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 60 mg
Description: Single oral 60-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 120 mg
Description: Single oral 120-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 160 mg
Description: Single oral 160-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 160 mg
Description: Single oral 160-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 320 mg
Description: Single oral 320-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 600 mg
Description: Single oral 600-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 900 mg
Description: Single oral 900-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 1200 mg
Description: Single oral 1200-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150
Description: Single oral dose-matched dose of Placebo for MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150
Description: Single oral dose-matched dose of Placebo for MK-8150
Study: NCT03815526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sport tape
Description: Dynamic tape apply 1 time
Study: NCT02369302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20141
Description: Tablet
Study: NCT01359449

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Group C Conjugate vaccine: MenC
Description: 0.5 mL, Intramuscular
Study: NCT00456547

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.
Study: NCT02604251

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone sheets
Description: Treatment of the surgical wounds with silicone sheets.
Study: NCT00748982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
Study: NCT02369302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20142
Description: Tablet
Study: NCT00748982

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
Study: NCT02369302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20141, DWC20142
Description: Tablet
Study: NCT01044264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Clindamycin/5% Benzoyl Peroxide Topical Gel
Description: Topical Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Clindamycin/5% Benzoyl Peroxide Topical Gel
Description: Topical Gel
Study: NCT01655381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8 mg/kg administered intravenously.
Study: NCT02443493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser
Description: Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham laser
Description: Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Study: NCT03722654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MTFS-I Installation
Description: MTFS-I Installation will focus on introducing MTFS-I components including weekly training modules and mock video segments to be coded, as well as monthly feedback reports summarizing therapist self-reported FT and CBT implementation in active cases. Facilitation will also be included to review progress and provide regular support.
Study: NCT00773240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazax
Description: 1 tablet, 75,000 SQ-T, daily during the trial period
Study: NCT03019107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath synchronized abdominal NMES
Description: VentFree prototype (VF03) that delivers electrical stimulation pulses to the abdominal muscles during exhalation with a frequency of 30 Hz, a pulse width of 350 µs and 90% of the maximum current that the participant can tolerate. These stimulation parameters were selected to cause a tetanic (continuous) contraction of the abdominal muscles, without pain for the patient. Stimulation will be administered for 30 minutes 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham breath synchronized abdominal NMES
Description: Modified VentFree prototype (VF03) that delivers stimulation pulses to the abdominal muscles during exhalation with a frequency of 10 Hz, a pulse width of 100 µs and current set to 10 milliamp. These stimulation parameters were chosen to cause a twitch contraction of the abdominal wall muscles. Stimulation will be administered for 30 minutes, 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
Study: NCT01192282

Intervention type: PROCEDURE
Intervention: Medical / Surgical Treatment
Description: All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
Study: NCT02081482

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET
Study: NCT02126956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800
Description: ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).
Study: NCT02905682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01857999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01595269

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: eHealth education
Description: In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eHealth education
Description: In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
Study: NCT01590810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150
Description: Single oral dose-matched dose of Placebo for MK-8150
Study: NCT00773240

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 placebo tablet, matching the active treatment, daily during the trial period